1 Landmark Square
104 articles with Loxo Oncology
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
Expands Illumina’s oncology offerings for NextSeq™ 550Dx with a companion diagnostic version of TruSight™ Tumor 170 for solid tumors
Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a companion diagnostic for Loxo Oncology’s larotrectinib and LOXO-292.
Loxo Oncology completed the rolling submission of its New Drug Application (INDA) to the U.S. FDA for larotrectinib for adult and pediatric metastatic solid tumors with an NTRK gene fusion. What has caught many investors, analysts and industry observers off-guard is the way the company has downpl...
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Bayer announced that its collaboration partner Loxo Oncology, Inc., has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of adult and pediatric patients.
Loxo Oncology Initiates Rolling Submission of NDA to FDA for Larotrectinib for the Treatment of TRK Fusion Cancers
The company expects to complete the NDA submission in early 2018.
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
These data are being presented today at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research in Atlanta.
Bayer Release: Updated Larotrectinib Pediatric Phase I Clinical Trial Data Demonstrates Response in TRK Fusion Cancers
These data are being presented today at the AACR Special Conference on Pediatric Cancer Research in Atlanta.
Investors have had a decent year, but some have much to be grateful for this Thanksgiving.
Loxo Oncology struck a deal with Bayer to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55B.
The company reported financial results for the third quarter ended September 30, 2017.
Loxo Oncology management will host a conference call to discuss these financial results, in addition to recent updates on development and corporate activities.
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
The full dataset is being reserved for a future publication.
Loxo Oncology Announces Details Of LOXO-292 Abstract To Be Presented As Late-Breaking Presentation At The IASLC 18th World Conference On Lung Cancer
Loxo Oncology Announces The Closing Of Its Follow-On Offering Of Common Stock And Full Exercise Of The Underwriters’ Option To Purchase Additional Shares
Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It
Loxo Oncology Announces Clinical Proof Of Concept Publication For Next-Generation TRK Inhibitor LOXO-195